Anlotinib Hydrochloride: Potent Multi-Target Tyrosine Kinase Inhibitor for Angiogenesis Research

Executive Summary: Anlotinib (hydrochloride) is a novel, orally bioavailable, multi-target tyrosine kinase inhibitor (TKI) that potently blocks VEGFR2, PDGFRβ, and FGFR1 activity in vitro and in vivo (Lin et al., 2018). The compound demonstrates nanomolar IC₅₀ values for its primary targets, surpassing sunitinib, sorafenib, and nintedanib in inhibitory efficacy. Mechanistically, it disrupts angiogenesis by inhibiting endothelial cell migration and tube formation, as well as downstream ERK signaling. Pharmacokinetic profiling reveals high oral bioavailability, broad tissue distribution, and favorable safety data in preclinical models. APExBIO's C8688 kit delivers validated, research-grade anlotinib hydrochloride for reproducible workflow integration in cancer and angiogenesis studies (APExBIO).

Biological Rationale

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a critical process both in development and in pathological contexts, including tumor growth and metastasis (Lin et al., 2018). Tumors exploit angiogenic pathways to secure nutrients and oxygen, primarily via the secretion of pro-angiogenic factors such as VEGF, PDGF-BB, and FGF-2. Inhibiting these signaling pathways disrupts tumor vascularization, representing a validated strategy in cancer therapy. Small-molecule tyrosine kinase inhibitors (TKIs) that target multiple angiogenic kinases are especially effective, as they address the redundancy and cross-talk among pro-angiogenic signals. Anlotinib hydrochloride exemplifies this approach by simultaneously targeting VEGFR2, PDGFRβ, and FGFR1, thereby offering comprehensive inhibition of tumor angiogenesis (related article).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib is a small-molecule inhibitor designed to competitively bind the ATP-binding domains of key tyrosine kinases:

• VEGFR2: Inhibition at IC₅₀ = 5.6 ± 1.2 nM (ATP-competitive, cell-based kinase assay at 37°C, pH 7.4).
• PDGFRβ: IC₅₀ = 8.7 ± 3.4 nM under equivalent assay conditions.
• FGFR1: IC₅₀ = 11.7 ± 4.1 nM.

This inhibition prevents receptor autophosphorylation after ligand binding (VEGF, PDGF-BB, FGF-2), halting downstream activation of the MAPK/ERK pathway. The result is a blockade of endothelial cell migration and capillary tube formation, both essential for neovascularization in tumor microenvironments (Lin et al., 2018). In EA.hy 926 human vascular endothelial cells, anlotinib demonstrates concentration-dependent inhibition of migration and tube formation in the presence of pro-angiogenic ligands. Comparative analyses show that anlotinib is more effective than sunitinib, sorafenib, and nintedanib in these mechanistic assays.

Evidence & Benchmarks

• Nanomolar IC₅₀ values for VEGFR2, PDGFRβ, and FGFR1 inhibition (5.6 ± 1.2 nM, 8.7 ± 3.4 nM, 11.7 ± 4.1 nM, respectively), outperforming established TKIs in matched assays (Lin et al., 2018).
• Significant suppression of VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and tube formation in vitro, measured by wound healing, chamber migration, and capillary tube formation assays (Fig. 2, Lin et al.).
• Superior anti-angiogenic efficacy compared to sunitinib, sorafenib, and nintedanib in both rat aortic ring and chicken chorioallantoic membrane (CAM) angiogenesis assays (Table 1, Lin et al.).
• Pharmacokinetic data: oral bioavailability 28–58% (rat), 41–77% (dog); plasma protein binding 93% (human); high tissue accumulation (lung, liver, kidney, tumor); blood-brain barrier penetration (preclinical models) (GSKChem summary).
• High median lethal dose (LD₅₀) of 1735.9 mg/kg in 14-day rat studies; no significant organ or genetic toxicity observed (APExBIO product page).

This article extends the comparative mechanistic insights presented in "Anlotinib Hydrochloride: Advanced Workflows for Tumor Ang..." by providing quantitative, condition-specific pharmacological data and direct head-to-head benchmarks.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is primarily used for research on tumor angiogenesis, anti-angiogenic signaling, and tyrosine kinase pathway modulation. The compound is validated in:

• Endothelial cell migration and tube formation inhibition assays (e.g., EA.hy 926 cells, 37°C, serum-free medium).
• Tumor microenvironment models (rat aortic ring, CAM assay).
• Pharmacokinetic profiling in preclinical species (rat, dog, human plasma protein binding).

Common Pitfalls or Misconceptions

• Not a clinical or diagnostic reagent: Anlotinib (hydrochloride) C8688 from APExBIO is strictly for research use; not approved for human or veterinary therapy (APExBIO).
• Kinase specificity: While highly selective for VEGFR2, PDGFRβ, and FGFR1, off-target effects may exist at supra-physiological concentrations.
• No effect in absence of pro-angiogenic stimuli: In cell-based assays lacking VEGF/PDGF-BB/FGF-2, anlotinib shows minimal inhibition of migration/tube formation.
• Not suitable for non-mammalian models without validation: Activity parameters are established primarily in human and rodent systems.
• Storage conditions: Compound stability is only validated for storage at -20°C; deviation can reduce potency (APExBIO Q&A).

This article updates the troubleshooting and workflow optimization focus of "Optimizing Tumor Angiogenesis Assays with Anlotinib (hydr...)" by integrating latest mechanistic and safety data.

Workflow Integration & Parameters

Researchers typically use anlotinib hydrochloride (SKU C8688) from APExBIO in the following protocols:

• Stock preparation: Dissolve at 10 mM in DMSO; aliquot and store at -20°C.
• Working concentrations: 1–100 nM for cell-based assays, with typical efficacy observed at 5–20 nM for endothelial migration/tube formation.
• Controls: Include vehicle (DMSO) and positive controls (sunitinib, sorafenib, nintedanib) for benchmarking (MAP-Kinase-Fragment summary).
• Readouts: Quantify migration (wound healing assay), tube length/network complexity (capillary tube assay), and microvessel density (CAM, aortic ring models).

For detailed troubleshooting and scenario-driven Q&A, the APExBIO kit documentation and related internal guides are recommended. This article clarifies the molecular rationale and pharmacological data underlying the protocols described in "Anlotinib Hydrochloride: Unraveling Multi-Target Angiogen...".

Conclusion & Outlook

Anlotinib hydrochloride, as formulated by APExBIO, represents a validated, potent, and selective research reagent for anti-angiogenic small molecule studies. Its nanomolar inhibition of VEGFR2, PDGFRβ, and FGFR1, together with favorable safety and pharmacokinetic profiles, make it the tool of choice for tumor angiogenesis research. Future work may further expand its applications in blood-brain barrier and tissue distribution studies. For research-use-only workflows, the Anlotinib (hydrochloride) C8688 kit from APExBIO offers superior reproducibility and benchmarked performance across angiogenesis assay systems.